Globally the incidence of obesity has reached epidemic proportions and still continues to rise. In fact, obesity is now recognized as the fifth leading cause of global death and arguably the number one health concern within developed countries ahead of heart disease and cancer. The negative effects of obesity have now been considered to outweigh that of smoking and alcohol abuse. In addition, obesity associated morbidities such as cardiovascular disease and type II diabetes are becoming an increasing burden for economy and healthcare. Obesity is now viewed as one of the most profound failures in pharmacotherapy, in part due to poor safety and efficacy reports of previous anti-obesity drugs as well as the lack of targets for new drug discoveries highlighting an unmet need for novel strategies. The 5-HT2C receptor is becoming a major target for the development of new anti-obesity therapeutics as this receptor is implicated in satiety stimulation, highlighted by the recent approval of Lorcaserin, a 5-HT2C agonist. Interestingly, recent studies have demonstrated a functional interaction between the 5-HT2C receptor and the receptor of the “hunger” hormone ghrelin, also known as the growth hormone secretagogue receptor (GHS-R1a). This suggests a potential novel mechanism of enhancing appetite regulation through functional cross talk of these two receptors. This study aims to investigate if there is a synergetic link between the appetite suppressing effects of the 5-HT2C receptor and GHS-R1a. In vitro analysis showed an attenuating effect of 5-HT2C receptor signalling on GHS-R1a-mediated intracellular calcium mobilization. Furthermore, examining cumulative food intake in C57Bl/6 mice it was established that there was a potentiation of ghrelin’s orexigenic effect following intraperitoneal (IP) administration of ghrelin in combination with the 5-HT2C antagonist SB242084, when compared to administration of ghrelin or SB242084 on their own. Following these results further studies will now be carried out to determine if there is an interaction between the appetite suppressing effects of the recently marketed 5-HT2C receptor specific agonist lorcaserin and the ghrelinergic system. The existence of a GHS-R1a/5-HT2C receptor dimer will enhance the pharmacological diversity and offer a novel pharmacological target for a range of feeding behaviours and functions relating to the ghrelinergic system including homeostatic appetite signalling and hedonic regulation of food intake behaviours.